Yarrow Bioscience Acquisition | Healthcare Deal in NJ

VYNE Therapeutics Inc. has completed the acquisition of Yarrow Bioscience, a healthcare services other business in New Jersey, for $0.0001. The merger acquisition brings Yarrow Bioscience into VYNE’s healthcare services footprint, supporting expansion of its operating platform in NJ acquisitions. Yarrow Bioscience acquisition activity fits broader healthcare M&A trends, with the buyer seeking to add capabilities and scale within healthcare services other. The merger acquisition is structured as a stock issuance registration under an SEC Form S-4/A, with Yellow Merger Sub Corp. merging into Yarrow and Yarrow surviving as a wholly owned subsidiary of VYNE.